Reviva Pharmaceuticals (NASDAQ:RVPH) Issues Quarterly Earnings Results

Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.10), FiscalAI reports.

Reviva Pharmaceuticals Stock Performance

NASDAQ RVPH traded down $0.06 during trading on Friday, hitting $0.33. 653,825 shares of the company’s stock traded hands, compared to its average volume of 599,755. The stock has a market capitalization of $4.26 million, a price-to-earnings ratio of -0.05 and a beta of 0.75. Reviva Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $23.20. The business has a 50 day moving average of $1.19 and a 200-day moving average of $5.88.

Get Reviva Pharmaceuticals alerts:

Institutional Investors Weigh In On Reviva Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC purchased a new stake in Reviva Pharmaceuticals during the 2nd quarter worth about $1,026,000. Millennium Management LLC increased its position in shares of Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after purchasing an additional 223,178 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Reviva Pharmaceuticals by 87.6% during the 4th quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock valued at $293,000 after purchasing an additional 489,711 shares during the last quarter. State Street Corp grew its position in Reviva Pharmaceuticals by 202.4% during the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock worth $107,000 after acquiring an additional 256,500 shares during the last quarter. Finally, NewEdge Advisors LLC bought a new position in Reviva Pharmaceuticals during the 1st quarter worth approximately $58,000. 63.18% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on RVPH. Maxim Group lowered Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, April 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Tuesday, April 21st. Wall Street Zen upgraded Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. Finally, D. Boral Capital downgraded Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 5th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $66.67.

View Our Latest Stock Report on Reviva Pharmaceuticals

About Reviva Pharmaceuticals

(Get Free Report)

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.

Featured Articles

• Five stocks we like better than Reviva Pharmaceuticals
• 3 Stocks to Own If Gas Prices Keep Rising
• 3 Crucial Aerospace Component Makers That Analysts Love
• Alphabet’s Googlebook Brings Gemini AI to PC Hardware
• Peloton Stock Gives Back Gains After Upbeat Earnings Report

Receive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.